SAM ISALY

Isaly studied at Cambridge and Harvard before going into finance. He spent time at the World Bank and various Wall Street firms before recognizing that healthcare was becoming the most investable sector in the world.

In 1989, he founded OrbiMed Advisors (originally called OrbiMed Capital). The thesis was simple but ahead of its time: healthcare spending was going to grow faster than the economy forever, and a dedicated specialist investor could outperform generalists.

He was right.

OrbiMed grew to manage over $18 billion across public equities, private equity, venture capital, and credit — all focused on healthcare. The firm invested in hundreds of biotech, pharma, and medical device companies.

It became the go-to investor for healthcare companies raising capital.

In 2021, the SEC charged Isaly with fraud, alleging he had cherry-picked trades — assigning winning trades to his personal accounts and losing trades to client funds. He settled with the SEC in 2022.

OrbiMed continued operating but Isaly’s reputation was permanently damaged.

OrbiMed Advisors is the main vehicle — one of the world’s largest healthcare-focused investment firms, managing over $18 billion. The firm invests across the full healthcare spectrum: biotechnology, pharmaceuticals, medical devices, healthcare services, and healthcare IT.

OrbiMed’s private equity and venture arms have backed hundreds of healthcare companies from early-stage startups to large-cap pharma. The public markets funds invested in publicly traded healthcare stocks globally.

Isaly was a healthcare specialist through and through. He didn’t invest in tech, didn’t buy banks, didn’t trade commodities.

Everything was healthcare. His edge was deep sector expertise — understanding FDA approval processes, clinical trial data, drug pipelines, and the regulatory landscape better than generalist investors.

The approach combined top-down thematic investing (aging population = more healthcare spending) with bottom-up stock picking (which specific company has the best drug pipeline). OrbiMed’s team included PhDs, MDs, and former industry executives who could evaluate scientific data that Wall Street analysts couldn’t.

Building OrbiMed from nothing to $18 billion in assets over three decades. The specific best trades are hard to pinpoint because the firm made thousands of investments, but OrbiMed was an early investor in numerous biotech companies that became multi-billion-dollar successes.

Their deep involvement in healthcare IPOs and secondaries gave them access to deals that generalist investors simply couldn’t get.

The SEC fraud charges. In 2021, the SEC alleged that Isaly had engaged in cherry-picking — allocating profitable trades to his personal accounts while dumping losing trades on client funds.

This is one of the most serious charges in investment management. He settled with the SEC in 2022, paying fines and penalties.

The charge stained what was otherwise one of the most impressive careers in healthcare investing.

The irony is extreme. A man who spent 30 years building a reputation as the most trusted name in healthcare investing was caught — allegedly — stealing from his own clients.

Isaly believed that healthcare was the greatest long-term investment theme of the 21st century. Aging populations globally, rising chronic disease rates, and accelerating biomedical innovation would drive healthcare spending to unprecedented levels.

A specialist investor who understood the science could capture outsized returns.

He also believed in building an institutional platform. OrbiMed wasn’t just a hedge fund — it was a full-spectrum healthcare investment firm with public, private, and credit arms.

This structure allowed the firm to invest in a company from startup to IPO to maturity.

Isaly is married and lives in the New York area. He has kept his family life private, especially since the SEC charges.

Before the scandal, he was a regular at healthcare industry conferences and charity events.

Cambridge University in England, then Harvard for graduate work. The international academic background served him well in building a global healthcare investment firm.

He also had stints at the World Bank, which gave him perspective on global healthcare systems.

As an Amazon Associate, Netfigo earns from qualifying purchases. Book links above may be affiliate links.